100Pcs BZX55C4V7 AL NEW DO35 500MM 4.7V ZENER DIODE VISHAY Zener Diodes


  1. Home
  2. 100Pcs BZX55C4V7 AL NEW DO35 500MM 4.7V ZENER DIODE VISHAY
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
100Pcs BZX55C4V7 VISHAY DIODE ZENER 4.7V 500MM DO35 NEW AL
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Country/Region of Manufacture: China
Brand:

Unbranded/Generic

Model:

BZX55C4V7

MPN:

Does not apply

UPC:

Does not apply





published on tue nov 09 2021

100Pcs BZX55C4V7 AL NEW DO35 500MM 4.7V ZENER DIODE VISHAY Zener Diodes

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

100Pcs BZX55C4V7 AL NEW DO35 500MM 4.7V ZENER DIODE VISHAY Zener Diodes

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS